tevogen.com (TVGN) - Profit After Payment of Taxes

TVGN (tevogen.com) - company brandmark

This chart of Tevogen Bio Holdings (TVGN) asset value demonstrates profit dynamics, which currently stand at -0.02. The company's success is based on attracting T-cell therapy experts through a system of stock options and academic independence. The business maintains a minimal environmental footprint due to the absence of manufacturing plants, while laboratory safety and efficient energy consumption in administrative offices remain priorities.

Net Income: Tevogen Bio Inc. (TVGN) for 02/21/2024 - 11/01/2026

Financial and market metric breakdowns for Tevogen Bio (TVGN)

- stock value and consensus price forecast:
Market Price Tevogen Bio Inc.|TVGN - Consensus Target
- market capitalization indicators:
Market Value Tevogen Bio Inc.|TVGN - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Tevogen Bio|TVGN - Company Net Assets|Market Value to Book Value Ratio tevogen.com|TVGN - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Capital Tevogen Bio Holdings|TVGN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Tevogen Bio Holdings Inc.|TVGN - Company Aggregate Debts|Debts to Book Value Tevogen Bio Inc.|TVGN - Company Long-Term Debt|Company Short-Term Indebtedness Tevogen Bio|Intermediate Coverage Ratio tevogen.com
- company profitability and valuation multiples indicators:
TVGN - Net Profit
Fundamental valuation:TVGN Tevogen Bio Inc.
Signature product of Tevogen Bio

Tevogen Bio Holdings (TVGN) profit serves as a fundamental indicator of operational efficiency, allowing for an assessment of business resilience through the lens of the net financial result. This metric measures the issuer's ability to generate cash flow after covering all expenses. By analyzing the company's profit dynamics, investors identify yield patterns and risks of cyclical drawdowns. For Tevogen Bio Holdings (TVGN), steady growth in this indicator confirms the commercial value of cell therapies, reflecting market confidence in innovative treatment methods for complex pathologies.

Main competitors

Company Net Income Biogen Idec (BIIB)|Net Income NBIX|RGC (regencellbioscience.com) - Profit After Payment of Taxes|Net Profit AXSM|ACAD - Company Net Income|Xenon Pharmaceuticals Inc - Net Income|Viking Therapeutics Corp - Company Net Income|SUPN - Company Net Income|Company Net Income catalystpharma.com|DNLI: Net Profit|Annual Net Income Harmony Biosciences Inc HRMY|BHVN (Biohaven Pharmaceutical) - Net Profit|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|praxismedicines.com - Company Profit|Anavex Life Sciences Corp. - Net Income|Final Profit CBLL|Prothena Biosciences - Net Profit|ALEC: Company Net Income|ANNX: Net Profit|OMER - Net Financial Result|Company Net Income Neurogene|Company Net Income AC Immune S.A. ACIU|Net Income VYGR (Voyager Pharma)|NMRA (Neumora Corp) - Final Profit|Net Profit SCLX (Scilex Holding Company)|Final Profit ACOG|CGTX - Company Net Income|Company Net Income Inhibikase Therapeutics Inc|Cassava (SAVA) - Company Net Income|ASRT (Assertio) - Company Net Income|COYA (Coya Therapeutics Inc) - Net Profit|Company Profit VTGN (VistaGen Therapeutics Inc)|Net Profit OVID|Net Financial Result Acumen Pharmaceuticals Inc.|Company Net Income CervoMed Inc CRVO|ATHE: Company Profit|Clene Nanomedicine - Net Profit|Annual Net Income PepGen Inc. (PEPG)|Jupiter Neurosciences Inc (JUNS) - Company Net Income|RLMD - Net Financial Result|Net Income ANVS|GRCE (Grace Tx) - Profit After Payment of Taxes|Net Income AIFF (Firefly Neuroscience, Inc)|Company Net Income KLTO (anewmeds.com)|Net Profit NRSN (NeuroSense Therapeutics Ltd.)|Annual Net Income Reviva Pharmaceuticals Holdings Inc.|MTVA - Company Net Income|NRXS (NeurAxis Inc) - Company Profit|heliusmedical.com (HSDT) - Company Net Income|Company Profit PASG|NEUP (Neuphoria Therapeutics, Inc.) - Net Profit|Company Net Income Minerva Neurosciences Inc NERV|Net Income ATHA (Athira)|Net Profit Addex (ADXN)|Company Net Income Alzamend Neuro ALZN|Final Profit CYCN|PTIX - Company Net Income|Company Net Income Pasithea Therapeutics|CRGT (cortigent.com) - Net Income|ATXI: Profit After Payment of Taxes|BCLI (Brainstorm Cell) - Net Profit|Company Net Income caratherapeutics.com CARA|Net Income CHRO (Chromocell Therapeutics Corp.)|Company Net Income ELYM (eliemtx.com)|Company Net Income Intra-Cellular Therapies, Inc. ITCI|Longboard (LBPH) - Company Net Income|Marinus Pharmaceuticals - Net Profit|Annual Net Income nkgenbiotech.com (NKGN)|NRBO: Net Profit|Company Net Income Sage Therapeutics Inc. (SAGE)|Company Net Income Neurotrope|Company Profit TRVN (Trevena Inc)|Net Income VIGL (Vigil Neuroscience)|WENA (Anew Medical Inc.) - Final Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)